Choice of replacement therapy for hemophilia - Cryoprecipitate issues: A rebuttal [10]

Journal of Thrombosis and Haemostasis

Volumn 2, Issue 6, 2004, Pages 1022-1023

  Farrugia, Albert ^a,b   Giangrande, P ^a  

^a WORLD FEDERATION OF HEMOPHILIA   (Canada)

^b Office of Devices   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 8 CRYOPRECIPITATE; CALCIUM; CITRIC ACID; FIBRINOGEN; RECOMBINANT BLOOD CLOTTING FACTOR 8;

APHERESIS; BLOOD ANALYSIS; BLOOD BANK; BLOOD COMPONENT; CALCIUM BLOOD LEVEL; DISEASE TRANSMISSION; DRUG QUALITY; DRUG SAFETY; ECONOMIC ASPECT; HEALTH CARE ACCESS; HEALTH CARE ORGANIZATION; HEAT TREATMENT; HEMOPHILIA; HUMAN; LETTER; PRIORITY JOURNAL; SUBSTITUTION THERAPY; THAWING; UNITED KINGDOM; VIRUS INACTIVATION; VIRUS INFECTION;

FACTOR VIII; FIBRINOGEN; HEMOPHILIA A; HUMANS; PRACTICE GUIDELINES; VIRUS INACTIVATION;

EID: 13244284715     PISSN: 15387933     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2004.00702.x     Document Type: Letter

References (5)

1. Shanbrom E. Choice of replacement therapy for hemophilia - reply to a rebuttal. J Thromb Haemost 2003; 1: 2699-70.
2. Rock GA, Cruickshank WH, Tackaberry ES, Palmer DS. Improved yields of FVIII from heparinized plasma. Vox Sang 1979; 36: 294-300.
3. Rock G. Methods that increase FVIII recovery in cryoprecipitate. J Thromb Haemost 2004; 2: 356-358.
4. Mason EC, Pepper DS, Griffin B. Production of cryoprecipitate of intermediate purity in a closed system thaw-siphon process. Thromb Haemost 1981; 46: 543-6.
5. Evatt B, Austin H, Leon G, Ruiz-Saez A, de Bosch N. Hemophilia treatment. Predicting the long-term risk of HIV exposure by cryoprecipitate. Haemophilia 2000; 6 (Suppl. 1): 128-32.